Search
Pomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Fludrocortisone
go.drugbank.com/drugs/DB00687ApprovedInvestigationalFludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.
Erythropoietin
go.drugbank.com/drugs/DB00016ApprovedInvestigationalEpoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.
Products: EPORATIO 20000 I E /1ML, EPORATIO 1000 I E /0.5MLHaemagglutinin-strain B (Victoria-like)
go.drugbank.com/drugs/DB15473ApprovedMixtures: Afluria Tetra Injektionssuspension in einer FertigspritzeLoncastuximab tesirine
go.drugbank.com/drugs/DB16222ApprovedInvestigationalZylonta also received approval in the EU on December 22, 2022. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.
Brompheniramine
go.drugbank.com/drugs/DB00835ApprovedHistamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.
Synonyms: 3-(p-bromophenyl)-3-(2-pyridyl)-N,N-dimethylpropylamine, 3-(4-bromophenyl)-N,N-dimethyl-3-(2-pyridinyl)-1-propanamineMixtures: M-end Wc, M-end PEApadamtase alfa
go.drugbank.com/drugs/DB15164ApprovedInvestigational[A262071] Apadamtase alfa, sold under the brand name Adzynma (ADAMTS13, recombinant-krhn), was approved by the FDA in November 2023 for use as an enzyme replacement therapy in patients with cTTP. … metalloproteinase with a thrombospondin type 1 motif, member 13), which is responsible for cleaving large von Willebrand factor multimers and preventing the formation of microthrombi - this deficiency in
Meningococcal polysaccharide vaccine group C
go.drugbank.com/drugs/DB13890ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Mixtures: Menjugate 10 Mikrogramm Injektionssuspension in einer Fertigspritze